{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T19:04:53Z","timestamp":1769799893182,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Health Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to determine whether there are differences in biologic treatment and complications according to subgroups of juvenile idiopathic arthritis (JIA) patients in adulthood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>HUR-BIO (Hacettepe University Rheumatology Biologic Registry) has been a single-center biologic disease-modifying anti-rheumatic drug registry since 2005. Patients were selected from HUR-BIO who met the International League of Associations for Rheumatology classification criteria for juvenile idiopathic arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Enthesitis-related arthritis (82, 49.1%), rheumatoid factor (-) polyarthritis (39, 23.4%), and rheumatoid factor (\u2009+) polyarthritis (26, 15.6%) were the most prevalent subgroups in 167 JIA patients. Etanercept (105, 62.9%), adalimumab (28, 16.8%), and infliximab (21, 12.6%) were the most prescribed first-line biologic drugs. Secondary failure was the most common reason for the treatment changes among 42 (43.3%) patients, followed by non-life-threatening side effects in 12 (12.4%) and primary failure in 11 (11.3%). Polyarticular JIA showed higher HAQ (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.020) and DAS28-ESR (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) before biologics and had a longer disease duration to initiation of biologic treatment than enthesitis-related arthritis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Only one patient (1.2%) in the enthesitis-related arthritis group needed the hip prosthesis, while 12 patients (18.5%) in the polyarticular JIA group required the same procedure (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In adult rheumatology departments, the most common JIAs present with ongoing disease are enthesitis-related arthritis and polyarthritis. Secondary failure was the main reason nearly half of the patients needed biologic changes during follow-up. The polyarticular group appears to have a higher disease severity and level of disability.\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                \u2022\n                                <jats:italic>The most of juvenile idiopathic arthritis patients in adult rheumatology clinics require biologics are enthesitis-related arthritis and polyarticular arthritis.<\/jats:italic>\n                                \u2022\n                                <jats:italic>Approximately half of the patients require biologic changes during follow-up, most of these due to secondary failure.<\/jats:italic>\n                                \u2022\n                                <jats:italic>Disease severity and disability appear to be higher in the polyarticular group, therefore treatment intensification may be considered.<\/jats:italic>\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-026-07938-x","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T05:43:03Z","timestamp":1768369383000},"page":"781-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of biologic drugs in juvenile idiopathic arthritis patients followed in an adult rheumatology clinic: real-life data from the HUR-BIO biologic registry"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9749-5585","authenticated-orcid":false,"given":"Emine B\u00fc\u015fra","family":"Ata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levent","family":"K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00fc\u015fra","family":"F\u0131rlatan Yazgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevgi G\u00f6zde","family":"Kart Bayram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Ekici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdin\u00e7","family":"\u00dcnald\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Aytu\u011f","family":"Ku\u015fta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bu\u011fu","family":"Bulat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6mer","family":"Karada\u011f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Akdo\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eule","family":"Apra\u015f Bilgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedat","family":"Kiraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130hsan","family":"Ertenli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yelda","family":"Bilginer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seza","family":"\u00d6zen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"2","key":"7938_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390\u2013392","journal-title":"J Rheumatol"},{"issue":"1","key":"7938_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12969-021-00629-8","volume":"19","author":"LN Zaripova","year":"2021","unstructured":"Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA (2021) Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J 19(1):135","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"7938_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00332-8","volume":"8","author":"A Martini","year":"2022","unstructured":"Martini A, Lovell DJ, Albani S, Brunner HI, Hyrich KL, Thompson SD et al (2022) Juvenile idiopathic arthritis. Nat Rev Dis Primers 8(1):5","journal-title":"Nat Rev Dis Primers"},{"key":"7938_CR4","doi-asserted-by":"crossref","unstructured":"Giancane G, Ruperto N, Paediatric Rheumatology International Trials O (2019) Treatment of juvenile idiopathic arthritis: what's new?. Curr Opin Rheumatol 31(5):428\u201335.","DOI":"10.1097\/BOR.0000000000000632"},{"issue":"4","key":"7938_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/annrheumdis-2016-210112","volume":"76","author":"HE Foster","year":"2017","unstructured":"Foster HE, Minden K, Clemente D, Leon L, McDonagh JE, Kamphuis S et al (2017) EULAR\/PRes standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Ann Rheum Dis 76(4):639\u2013646","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7938_CR6","first-page":"1086","volume":"36","author":"F Conti","year":"2018","unstructured":"Conti F, Pontikaki I, D\u2019Andrea M, Ravelli A, De Benedetti F (2018) Patients with juvenile idiopathic arthritis become adults: the role of transitional care. Clin Exp Rheumatol 36(6):1086\u20131094","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"7938_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.46497\/ArchRheumatol.2024.10749","volume":"39","author":"T Demirci Yildirim","year":"2024","unstructured":"Demirci Yildirim T, Isguder R, Karacura E, Erez Y, Makay B, Onen F et al (2024) Pediatric to adult rheumatology transition: Success rates, influencing factors, and evolving diagnoses and treatments. Arch Rheumatol 39(4):662\u2013669","journal-title":"Arch Rheumatol"},{"issue":"4","key":"7938_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361\u20138","journal-title":"Arthritis Rheum"},{"issue":"10","key":"7938_CR9","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/ard.2009.110767","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Jurik AG, Hermann KG, Landewe R, van der Heijde D, Baraliakos X et al (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group. Ann Rheum Dis 68(10):1520\u20131527","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7938_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/art.10863","volume":"48","author":"HE Foster","year":"2003","unstructured":"Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID (2003) Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 48(3):767\u2013775","journal-title":"Arthritis Rheum"},{"issue":"11","key":"7938_CR11","first-page":"1975","volume":"23","author":"DP Symmons","year":"1996","unstructured":"Symmons DP, Jones M, Osborne J, Sills J, Southwood TR, Woo P (1996) Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol 23(11):1975\u20131980","journal-title":"J Rheumatol"},{"issue":"5","key":"7938_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-021-00590-6","volume":"17","author":"PA Nigrovic","year":"2021","unstructured":"Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD et al (2021) Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol 17(5):257\u2013269","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"7938_CR13","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1136\/ard-2024-225851","volume":"83","author":"B Fautrel","year":"2024","unstructured":"Fautrel B, Mitrovic S, De Matteis A, Bindoli S, Anton J, Belot A et al (2024) EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Ann Rheum Dis 83(12):1614\u20131627","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7938_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F (2014) Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine 81(2):112\u2013117","journal-title":"Joint Bone Spine"},{"issue":"5","key":"7938_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.24953\/turkjped.2017.05.007","volume":"59","author":"M Cakan","year":"2017","unstructured":"Cakan M, Aktay-Ayaz N, Keskindemirci G, Ekinci DY, Karadag SG (2017) Subtype frequencies, demographic features, and remission rates in juvenile idiopathic arthritis - 265 cases from a Turkish center. Turk J Pediatr 59(5):548\u2013554","journal-title":"Turk J Pediatr"},{"issue":"1","key":"7938_CR16","first-page":"111","volume":"29","author":"E Demirkaya","year":"2011","unstructured":"Demirkaya E, Ozen S, Bilginer Y, Ayaz NA, Makay BB, Unsal E et al (2011) The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish paediatric rheumatology association. Clin Exp Rheumatol 29(1):111\u2013116","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"7938_CR17","doi-asserted-by":"publisher","first-page":"980","DOI":"10.24953\/turkjped.2023.22","volume":"65","author":"S Sener","year":"2023","unstructured":"Sener S, Basaran O, Batu ED, Cuceoglu MK, Balik Z, Aliyev E et al (2023) Choice and switch of biologic drugs in juvenile idiopathic arthritis. Turk J Pediatr 65(6):980\u2013989","journal-title":"Turk J Pediatr"},{"issue":"4","key":"7938_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/rheumatology\/kev398","volume":"55","author":"AF Mourao","year":"2016","unstructured":"Mourao AF, Santos MJ, Melo Gomes JA, Martins FM, Mendonca SC, Oliveira Ramos F et al (2016) Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt. Rheumatology (Oxford) 55(4):697\u2013703","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"7938_CR19","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s00296-023-05293-7","volume":"43","author":"A Felis-Giemza","year":"2023","unstructured":"Felis-Giemza A, Chmurzynska K, Kolodziejczyk B, Gazda A (2023) Revising diagnosis of juvenile idiopathic arthritis in adults: a single-center retrospective study. Rheumatol Int 43(7):1307\u20131311","journal-title":"Rheumatol Int"},{"issue":"9783","key":"7938_CR20","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken B, Albani S, Martini A (2011) Juvenile idiopathic arthritis. Lancet 377(9783):2138\u20132149","journal-title":"Lancet"},{"issue":"1","key":"7938_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-023-00897-6","volume":"21","author":"ML Pedersen","year":"2023","unstructured":"Pedersen ML, Neve-Graesboll A, Herlin T, Glerup M (2023) Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J 21(1):107","journal-title":"Pediatr Rheumatol Online J"},{"issue":"6","key":"7938_CR22","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells G, Becker J-C, Teng J, Dougados M, Schiff M, Smolen J et al (2009) Validation of the 28-joint disease activity score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 68(6):954\u2013960","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7938_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03166-9","volume":"25","author":"F Oliveira Ramos","year":"2023","unstructured":"Oliveira Ramos F, Rodrigues AM, Melo AT, Aguiar F, Brites L, Azevedo S et al (2023) Influence of the timing of biological treatment initiation on juvenile idiopathic arthritis long-term outcomes. Arthritis Res Ther 25(1):177","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-07938-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-07938-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-07938-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:03:05Z","timestamp":1769763785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-07938-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7938"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-07938-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee approved the study of Hacettepe University Faculty of Medicine (No. GO 15\/788) and was performed in accordance with the ethical standards laid down in the Declaration of Helsinki of 1975\/83. All participants gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written informed consent for the publication of their clinical data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have any conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}